FDA Warns of the Dangers of 'Vaginal Rejuvenation'

Share this content:
FDA Warns of the Dangers of 'Vaginal Rejuvenation'
FDA Warns of the Dangers of 'Vaginal Rejuvenation'

TUESDAY, July 31, 2018 (HealthDay News) -- Despite their growing popularity, there's no evidence that so-called "vaginal rejuvenation" procedures are either safe or effective, according to a statement released by the U.S. Food and Drug Administration.

The procedures, which use lasers and other energy-based devices to remove or reshape vaginal tissue, claim to treat conditions and symptoms related to menopause, urinary incontinence, or sexual function. But in a statement released Monday, the FDA said it's identified numerous cases of vaginal burns or scarring tied to "vaginal rejuvenation," as well as post-procedural pain during sexual intercourse or recurring or chronic pain.

In some cases, women who've gone into early menopause after breast cancer treatments are opting for these interventions, but "the deceptive marketing of a dangerous procedure with no proven benefit, including to women who've been treated for cancer, is egregious," FDA Commissioner Scott Gottlieb, M.D., said in the statement. "The deceptive marketing of unproven treatments may not only cause injuries but may also keep some patients from accessing appropriate, recognized therapies to treat severe medical conditions."

The FDA recently notified seven device manufacturers about inappropriate marketing of their devices for "vaginal rejuvenation" procedures, Gottlieb pointed out. The companies are: Alma Lasers, BTL Aesthetics, BTL Industries, Cynosure, InMode, Sciton, and Thermigen. They were given 30 days to address the FDA's concerns. If they fail to respond in that time, the FDA said it would consider its next actions, which could include enforcement measures.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves First Customizable Insulin Pump

FDA Approves First Customizable Insulin Pump

Product works by delivering insulin under the skin at set or variable rates

Sepsis Common in Terminal Hospitalizations, Discharges

Sepsis Common in Terminal Hospitalizations, Discharges

Most common underlying causes of death in sepsis are solid and hematologic cancers, chronic heart disease

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer older men than women, even with higher risk, undergo DXA screening, 25(OH)D measurement

is free, fast, and customized just for you!




Already a member?

Sign In Now »